⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO
Form 8-K
sec.gov
XNCR
Xencor Reports First Quarter 2026 Financial Results
businesswire.com
XNCR
Form 8-K
sec.gov
XNCR
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
businesswire.com
XNCR
TIME roept Xenco Medical uit tot een van de 100 meest invloedrijke bedrijven ter wereld van TIME en winnaar van de 2026 TIME100 Impact Award in Gezondheid
businesswire.com
XNCR
Form 8-K
sec.gov
XNCR
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & Outlook
globenewswire.com
JNJ
AMGN
GMAB
ABBV
AZN
PFE
BMY
REGN
XNCR
ZYME
Ledger Run First to Bring AI-Powered Automation to Clinical Trial Payments
prnewswire.com
XNCR
Antheia Appoints Dr. Chris Savile as Vice President of Business Development and Partnerships
prnewswire.com
XNCR
CDXS